Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention
Purpose of Review Discuss the prognostic significance of kidney flares in patients with lupus nephritis, associated risk factors, and possible preventative strategies. Recent Findings Recently performed clinical trials and observational cohort studies underscore the high frequency of relapses of kidney disease, following initial response, in patients with proliferative and/or membranous lupus nephritis. Analysis of hard disease outcomes such as progression to chronic kidney disease or end-stage kidney disease, coupled with histological findings from repeat kidney biopsy studies, have drawn attention to the importance of renal function preservation that should be pursued as early as lupus nephritis is diagnosed. In this respect, non-randomized and randomized evidence have suggested a number of factors associated with reduced risk of renal flares such as attaining a very low level of proteinuria (< 700–800 mg/24 h by 12 months), using mycophenolate over azathioprine, adding belimumab to standard therapy, maintaining immunosuppressive/biological treatment for at least 3 to 5 years, and using hydroxychloroquine. Other factors that warrant further clarification include serological activity and the use of repeat kidney biopsy to guide the intensity and duration of treatment in selected cases. Summary The results from ongoing innovative studies integrating kidney histological and clinical outcomes, together with an expanding spectrum of therapies in lupus nephritis, are expected to facilitate individual medical care and long-term disease and patient prognosis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Current rheumatology reports - 25(2023), 10 vom: 15. Juli, Seite 183-191 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Banos, Aggelos [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Biologic agents |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s11926-023-01109-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053090276 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053090276 | ||
| 003 | DE-627 | ||
| 005 | 20230916064907.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230916s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11926-023-01109-6 |2 doi | |
| 035 | |a (DE-627)SPR053090276 | ||
| 035 | |a (SPR)s11926-023-01109-6-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Banos, Aggelos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Purpose of Review Discuss the prognostic significance of kidney flares in patients with lupus nephritis, associated risk factors, and possible preventative strategies. Recent Findings Recently performed clinical trials and observational cohort studies underscore the high frequency of relapses of kidney disease, following initial response, in patients with proliferative and/or membranous lupus nephritis. Analysis of hard disease outcomes such as progression to chronic kidney disease or end-stage kidney disease, coupled with histological findings from repeat kidney biopsy studies, have drawn attention to the importance of renal function preservation that should be pursued as early as lupus nephritis is diagnosed. In this respect, non-randomized and randomized evidence have suggested a number of factors associated with reduced risk of renal flares such as attaining a very low level of proteinuria (< 700–800 mg/24 h by 12 months), using mycophenolate over azathioprine, adding belimumab to standard therapy, maintaining immunosuppressive/biological treatment for at least 3 to 5 years, and using hydroxychloroquine. Other factors that warrant further clarification include serological activity and the use of repeat kidney biopsy to guide the intensity and duration of treatment in selected cases. Summary The results from ongoing innovative studies integrating kidney histological and clinical outcomes, together with an expanding spectrum of therapies in lupus nephritis, are expected to facilitate individual medical care and long-term disease and patient prognosis. | ||
| 650 | 4 | |a Systemic lupus erythematosus |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a End-stage kidney disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Risk stratification |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Therapeutic target |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Flares |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Biologic agents |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Bertsias, George |0 (orcid)0000-0001-5299-1406 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current rheumatology reports |d Philadelphia, Pa. : Current Science Inc., 1999 |g 25(2023), 10 vom: 15. Juli, Seite 183-191 |w (DE-627)SPR023029005 |w (DE-600)2094184-5 |x 1534-6307 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:10 |g day:15 |g month:07 |g pages:183-191 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11926-023-01109-6 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 10 |b 15 |c 07 |h 183-191 | ||